GEN Exclusives

More »

GEN News Highlights

More »
Jul 21, 2008

Gamida Obtains Rights to Amgen Cytokines to Produce Stem Cell Cancer Drug

  • Gamida Cell will use a number of cytokines from Amgen to manufacture StemEx for its pivotal registration study and subsequent commercialization. The product is being developed for hematological malignancies by Gamida Cell in a joint venture with Teva Pharmaceutical.

    Under the terms of the nonexclusive license agreement, Amgen will receive a minority equity interest in Gamida Cell in addition to royalties from sales related to hematological indications.

    StemEx is composed of ex vivo expanded cord blood stem/progenitor cells that are transplanted with nonexpanded cells from the same unit. In November 2007, the first patient enrolled in the international, multicenter trial, underwent a StemEx transplant.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Sustainability in New Dietary Guidelines

Do you think that sustainability considerations should be incorporated into the new Dietary Guidelines for Americans?

More »